ARS Pharmaceuticals reported revenue of $33.66M and net income of -$62.38M for the quarter ended Jun 2026, up 114.2% year over year. This income statement covers 26 quarters of results from Mar 2020 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Mar2020 | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue & cost | ||||||||||||||||||||||||||
| Revenue | 0.66M | 0.46M | 0.19M | 0.02M | 0.01M | 0.50M | 2.07M | 86.58M | 7.97M | 15.72M | 32.50M | 28.09M | 22.68M | 33.66M | ||||||||||||
| Cost of RevenueCost of Rev | 0.11M | 0.86M | 1.09M | 4.98M | 8.19M | 6.15M | 6.29M | 12.85M | ||||||||||||||||||
| Gross Profit | 0.50M | 1.96M | 85.72M | 6.88M | 10.73M | 24.31M | 21.93M | 16.39M | 20.81M | |||||||||||||||||
| Operating items | ||||||||||||||||||||||||||
| Research & DevelopmentR&D | 15.64M | -25.36M | 5.42M | 4.35M | 3.89M | 4.71M | 6.55M | 7.31M | 3.00M | 3.40M | 5.23M | 6.90M | 4.42M | 3.03M | 2.95M | 4.04M | 2.75M | 3.44M | 4.34M | 4.70M | ||||||
| Selling, General & AdministrativeSG&A | 7.04M | -15.76M | 2.34M | 2.46M | 2.93M | 10.73M | 12.18M | 13.30M | 14.98M | 6.82M | 7.96M | 8.94M | 19.28M | 35.49M | 41.10M | 54.31M | 74.75M | 59.95M | 72.20M | 77.58M | ||||||
| Other Operating ExpensesOther Opex | -1.09M | 0.11M | 0.86M | 1.09M | 4.98M | 8.19M | 6.15M | 6.29M | 12.85M | |||||||||||||||||
| Operating ExpensesOpex | 22.68M | -41.12M | 7.76M | 6.81M | 6.82M | 15.44M | 18.73M | 20.61M | 17.98M | 10.23M | 13.19M | 15.84M | 23.82M | 39.38M | 45.15M | 63.33M | 85.69M | 69.55M | 82.83M | 95.12M | ||||||
| Operating IncomeOp. Inc | -22.68M | 46.62M | -7.10M | -6.34M | -6.63M | -15.44M | -18.71M | -20.60M | -17.98M | -10.23M | -13.19M | -15.34M | -21.75M | 47.20M | -37.18M | -47.61M | -53.19M | -41.47M | -60.15M | -61.47M | ||||||
| EBIT | -22.68M | 46.62M | -7.10M | -6.34M | -6.63M | -15.44M | -18.71M | -20.60M | -17.98M | -10.23M | -13.19M | -15.34M | -21.75M | 47.20M | -37.18M | -47.61M | -53.19M | -41.47M | -60.15M | -61.47M | ||||||
| Non-operating items | ||||||||||||||||||||||||||
| Non Operating Interest Expenses | 2.44M | 2.48M | ||||||||||||||||||||||||
| Interest & Investment IncomeInt & Inv Inc | -0.03M | 0.03M | 0.41M | -0.34M | -0.25M | 0.02M | 0.21M | -0.17M | -0.02M | 0.48M | -0.12M | -0.15M | -0.12M | 0.04M | 0.13M | -0.22M | -0.04M | |||||||||
| Other Non Operating IncomeOther Non Op Inc. | -0.15M | -0.08M | 0.05M | 1.15M | 3.75M | 3.23M | 3.11M | 3.06M | 2.90M | 2.82M | 2.62M | 3.02M | 3.24M | 2.73M | 2.04M | 2.66M | 1.97M | 1.60M | ||||||||
| Net income details | ||||||||||||||||||||||||||
| EBT | -22.71M | 46.66M | -7.10M | -6.34M | -6.63M | -15.04M | -19.05M | -20.85M | -17.96M | -10.02M | -13.37M | -15.36M | -21.26M | 47.08M | -37.33M | -47.73M | -53.15M | -41.33M | -62.81M | -63.99M | ||||||
| Profit After TaxPAT | -22.69M | 45.81M | -7.25M | -6.42M | -6.58M | -14.43M | -15.30M | -17.62M | -14.87M | -6.96M | -10.46M | -12.54M | -19.13M | 50.10M | -34.09M | -45.00M | -51.15M | -41.19M | -60.84M | -62.38M | ||||||
| Income from Continuing OperationsIncome (Continuing) | -22.71M | 46.66M | -7.10M | -6.34M | -6.63M | -15.04M | -19.05M | -20.85M | -17.96M | -10.02M | -13.37M | -15.36M | -21.26M | 47.08M | -37.33M | -47.73M | -53.15M | -41.33M | -62.81M | -63.99M | ||||||
| Consolidated Net IncomeConsol Net Inc. | -22.71M | 46.66M | -7.10M | -6.34M | -6.63M | -15.04M | -19.05M | -20.85M | -17.96M | -10.02M | -13.37M | -15.36M | -21.26M | 47.08M | -37.33M | -47.73M | -53.15M | -41.33M | -62.81M | -63.99M | ||||||
| Income towards Parent CompanyParent Net Inc | -22.71M | 46.66M | -7.10M | -6.34M | -6.63M | -15.04M | -19.05M | -20.85M | -17.96M | -10.02M | -13.37M | -15.36M | -21.26M | 47.08M | -37.33M | -47.73M | -53.15M | -41.33M | -62.81M | -63.99M | ||||||
| Net Income towards Common StockholdersNet Income | -22.71M | 46.66M | -7.10M | -6.34M | -6.63M | -15.04M | -19.05M | -20.85M | -17.96M | -10.02M | -13.37M | -15.36M | -21.26M | 47.08M | -37.33M | -47.73M | -53.15M | -41.33M | -62.81M | -63.99M | ||||||
| Additional items | ||||||||||||||||||||||||||
| EPS (Basic) | -0.65 | 1.34 | -0.20 | -0.18 | -0.19 | -0.38 | -0.20 | -0.22 | -0.19 | -0.11 | -0.14 | -0.16 | -0.22 | 0.49 | -0.38 | -0.49 | -0.54 | -0.42 | -0.63 | -0.64 | ||||||
| EPS (Diluted) | -0.65 | 1.62 | -0.23 | -0.21 | -0.19 | -0.38 | -0.20 | -0.22 | -0.19 | -0.11 | -0.14 | -0.16 | -0.22 | 0.46 | -0.38 | -0.49 | -0.54 | -0.42 | -0.63 | -0.64 | ||||||
| Shares Outstanding | 35.00M | 34.93M | 35.11M | 35.13M | 35.46M | 39.96M | 94.23M | 94.91M | 95.58M | 95.22M | 96.49M | 96.83M | 97.03M | 96.94M | 98.06M | 98.36M | 98.81M | 98.57M | 99.30M | 99.31M | ||||||
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 35.00M | 28.87M | 30.37M | 30.61M | 35.46M | 39.96M | 94.23M | 94.91M | 95.58M | 95.22M | 96.49M | 96.83M | 97.03M | 102.39M | 98.06M | 98.36M | 98.81M | 98.57M | 99.30M | 99.31M | ||||||
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 35.04M | 35.11M | 35.12M | 35.17M | 35.88M | 39.96M | 94.45M | 95.32M | 95.80M | 96.41M | 96.57M | 96.94M | 97.15M | 97.95M | 98.13M | 98.70M | 98.84M | 99.29M | 99.30M | 99.44M | ||||||
| EBITDA | -22.68M | 46.62M | -7.10M | -6.34M | -6.63M | -15.44M | -18.71M | -20.60M | -17.98M | -10.23M | -13.19M | -15.34M | -21.75M | 47.20M | -37.18M | -47.61M | -53.19M | -41.47M | -60.15M | -61.47M | ||||||
| Interest ExpensesInt Expense | 2.44M | 2.48M |